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squamous cell ca. 21.4%/14.0%, BAC 2.4%/16.3%, others 
19.1%/6.9%. Median age was 60 years (range 21-74). R was given on 
arm 1 as 2nd line therapy in 64.3% of pts., as 3rd line in 35.7% and on 
arm 2 as 3rd line in 58.1%, as 4th line in 41.9%. 90.6% pts had stage 
IV disease. The trial did not proceed to stage 2 based on RR for 74 pts 
in the efﬁcacy population. Best overall tumor response (arm 1/2 in %): 
conﬁrmed PR (5.3/2.8) and SD (44.7/44.4). Median PFS is 11.3 weeks 
(95% CI: 8.1; 12.4) in arm 1 and 9.7 weeks (7.3; 13.0) in arm 2. Out 
of 42 (arm 1) and 43 (arm 2) patients in the intent-to-treat population, 
22 and 17 respectively achieved a best overall response of SD or better 
(CR+PR): in arm 1 duration of SD observed at the cut-off date ranged 
from 49 days (censored) to 267 days (8 pts have duration of SD>3 
months) and in arm 2 from 68 to 231 days (11 pts have duration of 
SD>3 months). Most frequent AEs (pts, all grades/grade 3&4): stoma-
titis/mucositis (43/5), cough (27/1), dyspnea (33/8), rash (26/0), fatigue 
(25/10), anorexia (25/1), nausea (20/0), anemia (18/3), epistaxis (18/0), 
diarrhea (17/2). IHC analyses of tumor tissue samples conﬁrmed that 
high levels of pEGFR correlate with activation (upregulation) of the 
p-AKT. Detailed analyses will be presented.
Conclusions: 10 mg qd R monotherapy is well tolerated and shows 
limited activity in pretreated advanced NSCLC pts with respect to 
response. R effect in disease control has to be further investigated. 
Combination trials with both standard chemotherapy and targeted 
agents are ongoing.
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Background: Talactoferrin alfa (TLF), an orally active immunomodu-
latory protein, acts at the gut through a novel mechanism of action. In 
animal experiments, TLF bound enterocyte receptors and immune cells 
in the Peyer’s patches, induced DC maturation, and initiated an immu-
nostimulatory cascade in the Gut Associated Lymphoid Tissue (GALT), 
with activation of innate and adaptive immunity. GALT immunomodu-
lation was followed by systemic increases in NK and CTL activity, 
activation of tumor-draining lymph nodes, and cellular inﬁltration of 
distant tumors. Talactoferrin showed anti-cancer activity in preclinical 
experiments and in non-small cell lung cancer (NSCLC) patients in 
Phase 1b studies. Two randomized, placebo-controlled Phase 2 NSCLC 
studies were conducted with TLF as a single agent and combined with 
carboplatin and paclitaxel. The 110-patient combination therapy study 
(previously presented) met its primary endpoint with an improved over-
all response over chemotherapy alone. We now present results from the 
placebo-controlled single agent study.
Methods: 100 Stage IIIB/IV NSCLC patients who had progressed after 
ﬁrst- or second-line therapy were enrolled at 10 leading Indian cancer 
centers, and randomized to receive supportive care plus either oral TLF 
(1.5 g bid) or placebo. TLF/placebo was administered, for up to three 
14-week cycles (12 weeks on, 2 weeks off), in a centrally monitored 
trial. The primary endpoint was overall survival (OS) with 80% power 
to detect an improvement in median OS with a 1-tailed α=0.05. 
Results: All patients had previously received a 1st line platinum based 
regimen; 25 also received 2nd line therapy. The TLF and placebo arms 
enrolled 47 and 53 patients, respectively. Baseline characteristics were 
similar in both groups, including proportion of patients receiving 1 or 2 
prior regimens. All patients were included in the Intent To Treat (ITT) 
analysis. 
The trial met its primary endpoint with a 62% increase in median OS 
(2.3 months; HR 0.69; p<0.05). The talactoferrin effect was also seen 
in relevant subsets, including patients with Stage IIIB or IV disease, 
ECOG 0 or 1, or one/two prior therapies. TLF was well tolerated; 
adverse events (AEs) were generally mild. No drug-related serious AEs 
were reported, and the incidence of total AEs and Grade 3/4 AEs was 
similar in both arms. 
Conclusion: Oral talactoferrin, a promising new anti-cancer agent, 
signiﬁcantly improved survival in patients with refractory NSCLC in 
this randomized, placebo-controlled trial. TLF was well tolerated in this 
population. Given its favorable toxicity proﬁle, TLF may be particu-
larly attractive in refractory patients with poor performance status.
Figure. Kaplan Meier Curves (Months)
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Background: The Eastern Co-operative Oncology Group (ECOG) 
4599 phase III trial demonstrated that the addition of bevacizumab 
to carboplatin/paclitaxel (CP) signiﬁcantly improved overall survival 
and progression-free survival (PFS) in patients with advanced non-
squamous non-small cell lung cancer (NSCLC) [Sandler et al., NEJM 
2006;355:2542-50]. Cisplatin/gemcitabine (CG) is a combination com-
monly used in Europe and other regions outside of the USA. In order 
to establish the efﬁcacy of bevacizumab in combination with cisplatin-
based doublets, the BO17704 trial investigated the effect of the addition 
of bevacizumab to CG on PFS in patients with advanced NSCLC.
Methods: This randomised, placebo-controlled, multicentre 3-arm 
phase III study compared the efﬁcacy of two doses of bevacizumab in 
combination with CG versus CG plus placebo. The primary endpoint 
was to demonstrate superiority in PFS in both bevacizumab-contain-
ing treatment arms versus the control regimen. Secondary endpoints 
were overall survival, response rate and safety. Eligibility criteria were 
histologically or cytologically documented previously untreated locally 
advanced, metastatic or recurrent non-squamous NSCLC; ECOG per-
formance status 0-1; adequate haematological, renal and liver function; 
no brain metastases; no history of recent CTC grade ≥2 haemoptysis. 
Between February 2005 and August 2006, a total of 1,043 patients were 
randomised 1:1:1 to three treatment groups. One group received up to 
6 cycles of C 80mg/m2 on day 1 and G 1,250mg/m2 on day 1 and day 
8 every 3 weeks plus placebo (n=347). The second group received CG 
chemotherapy plus bevacizumab at a dose of 7.5mg/kg every 3 weeks 
(n=345), and the third group received CG chemotherapy plus beva-
cizumab at a dose of 15mg/kg every 3 weeks (n=351). Bevacizumab 
was to be administered until disease progression for both bevacizumab 
arms. Data cut-off was two months after the last patient was enrolled.
Results: Bevacizumab at a dose of 7.5 or 15mg/kg every 3 weeks in 
combination with CG chemotherapy signiﬁcantly prolonged PFS in pa-
tients with advanced NSCLC when compared with CG chemotherapy 
plus placebo. The treatment effects observed in the two bevacizumab-
containing arms were similar. No new safety signals associated with the 
use of bevacizumab were observed for either bevacizumab dose in this 
clinical setting.
Conclusions: The trial met its primary endpoint. Final efﬁcacy and 
safety results for each arm will be presented at the meeting.
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Background: Acquired resistance to geﬁtinib in NSCLC patients 
with somatic activating EGFR mutations has been associated with 
the development of a secondary T790M mutation in about 50% of the 
patients. The mechanisms for acquired resistance in the remaining 
tumors are still unknown. Heat shock protein 90 (Hsp90) is a molecular 
chaperone that plays a key role in the conformational maturation of 
oncogenic signaling proteins and has become an exciting therapeutic 
target for the treatment of cancer. IPI-504, the highly soluble hydro-
quinone hydrochloride derivative of 17-AAG, was synthesized as an 
Hsp90 inhibitor with favorable pharmaceutical properties. Herein, we 
explored new therapeutic strategies overcoming the EGFR T790M and 
non-T790M geﬁtinib-resistance mechanisms. Methods and Results: We 
have developed geﬁtinib-resistant (GR) clones from geﬁtinib-hyper-
sensitive EGFR L858R mutant (H3255) and EGFR exon 19 deletion 
(del E746_A750) mutant (HCC827) NSCLC cell lines by exposing 
them to increasing concentrations of geﬁtinib in vitro. Analyses of the 
resistant cells demonstrate that H3255 GR contain an EGFR T790M 
mutation which is not observed in HCC827 GR cells. We investigated 
the effects of IPI-504 on cells according to the mechanism of resistance 
to geﬁtinib; KRAS mutation (A549 and H441), EGFR T790M mutation 
(H1975 and H3255GR) and non-T790M mutation (HCC827GRs). In 
time course experiments, mutant EGFR proteins in H1975, H3255GR 
and HCC827GRs were depleted after only 6 hrs of exposure to 100 
nM IPI-504, while diminution of wild-type EGFR in A549 and H441 
was less substantial. However, several client proteins for Hsp90 were 
equally affected among these cell lines. Exposure to IPI-504 showed 
dose and time dependent growth inhibition exhibiting IC50 values for 
cell viability at 72 h that ranged from 41 - 293nM. All cell lines tested 
were found to be sensitive to IPI-504 regardless of geﬁtinib-resistance 
mechanisms. When geﬁtinib was combined, IPI-504 also showed 
synergism with Combination Indices (CI) at the IC50 and further stud-
ies are ongoing to evaluate for potential synergy with geﬁtinib. Flow 
cytometric Tunel assay and ﬂuorescent-based casspase 3/7 in H1975, 
H3255GR and HCC827GR with mutant EGFR showed that the 48 hr 
treatment with 1.0uM IPI-504 caused an increase in sub-G1 fraction 
and apoptosis. 
Conclusions: These data support the conclusion that mutational activa-
tion of EGFR is associated with dependence on Hsp90 for stability. 
Taken together, IPI-504 represents a novel strategy for the treatment 
of NSCLC patients having EGFR T790M or non-T790M geﬁtinib-re-
sistance mechanism and suggests an important implication for clinical 
development.
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Study Objective: Protocols using indction chemotherapy for advanced 
lung cancer are more frequently used with the hope that surgery can be 
performed after the cancer is downstaged. The current restaging mo-
dalities either have a low diagnostic accuracy (computed tomography) 
or can be technically difﬁcult (Re-, mediastinoscopy). Endobronchial 
ultrasound guided TBNA is an excellent tool for mediastinal lymph 
node staging and may have a role in restaging also. 
